Trial Profile
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs Colestipol (Primary) ; Ezetimibe (Primary) ; Niacin (Primary) ; HMG-CoA reductase inhibitors
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- 05 Nov 2005 New trial record.